Go Pro

Mainz Biomed (QUCY) Stock Price, News & Analysis

$1.30 -0.06 (-4.41%)
As of 08/21/2026 04:00 PM Eastern

About Mainz Biomed Stock (NASDAQ:QUCY)

Advanced

Key Stats

Today's Range
$1.27
$1.36
50-Day Range
$1.06
$2.12
52-Week Range
$0.30
$4.93
Volume
1.04 million shs
Average Volume
770,260 shs
Market Capitalization
$19.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

Mainz Biomed Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

QUCY MarketRank™: 

Mainz Biomed scored higher than 33% of companies evaluated by MarketBeat, and ranked 540th out of 661 stocks in the industrials sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Mainz Biomed has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 strong buy rating, no buy ratings, 2 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Mainz Biomed has only been the subject of 3 research reports in the past 90 days.

  • Read more about Mainz Biomed's stock forecast and price target.
  • Earnings Growth

    Earnings for Mainz Biomed are expected to grow in the coming year, from ($0.49) to ($0.19) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Mainz Biomed is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Mainz Biomed is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Mainz Biomed has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    18.04% of the float of Mainz Biomed has been sold short.
  • Short Interest Ratio / Days to Cover

    Mainz Biomed has a short interest ratio ("days to cover") of 4.36.
  • Change versus previous month

    Short interest in Mainz Biomed has recently decreased by 8.63%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Mainz Biomed does not currently pay a dividend.

  • Dividend Growth

    Mainz Biomed does not have a long track record of dividend growth.

  • News Sentiment

    Mainz Biomed has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Industrials companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Mainz Biomed this week, compared to 4 articles on an average week.
  • Search Interest

    Only 4 people have searched for QUCY on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Mainz Biomed to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Mainz Biomed insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    3.10% of the stock of Mainz Biomed is held by insiders.

  • Percentage Held by Institutions

    Mainz Biomed has minimal institutional ownership at this time.

  • Read more about Mainz Biomed's insider trading history.
Receive QUCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mainz Biomed and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

QUCY Stock News Headlines

Mainz Biomed Q3 EPS Lifted by Litchfield Hills Research
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's pullback from highs above 4000 an ounce. Yet top junior mining assets remain priced as if gold were still stuck near 1800 an ounce, a gap analyst Garrett Goggin calls the Golden Anomaly. With record cash on hand, majors may soon be forced to buy juniors to secure future production.tc pixel
Litchfield Hills Research Forecasts Mainz Biomed Q2 Earnings
Mainz Biomed (NASDAQ:QUCY) Upgraded at Litchfield Hills Research
See More Headlines

QUCY Stock Analysis - Frequently Asked Questions

Mainz Biomed's stock was trading at $0.7374 on March 13, 2026. Since then, QUCY shares have increased by 76.3% and is now trading at $1.30.

Shares of QUCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
8/21/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Aerospace & Defense
Sub-Industry
Aerospace & Defense
Current Symbol
NASDAQ:QUCY
CIK
1874252
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.56
Quick Ratio
2.11

Sales & Book Value

Annual Sales
$537.08 thousand
Price / Sales
35.49
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.38 per share
Price / Book
0.94

Miscellaneous

Outstanding Shares
14,661,000
Free Float
14,207,000
Market Cap
$19.06 million
Optionable
N/A
Beta
2.31
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:QUCY) was last updated on 8/22/2026 by MarketBeat.com Staff.
From Our Partners